首页> 外文期刊>The New England journal of medicine >TET2 and DNMT3A mutations in human T-cell lymphoma.
【24h】

TET2 and DNMT3A mutations in human T-cell lymphoma.

机译:TET2和DNMT3A在人T细胞淋巴瘤中的突变。

获取原文
获取原文并翻译 | 示例
           

摘要

to the editor: Despite the poor prognosis of T-cell lymphomas, the genetic basis of these cancers is poorly defined. We have found acquired TET2 mutations in both human myeloid cancers and T-cell lymphoma. TET proteins are involved in the epigenetic control of transcription, at least through the oxidation of methylated cytosines and DNA demethylation.The catalytic activity of the TET proteins is inhibited by 2-hydroxygluta-rate, an oncogenic metabolite produced by the mutated forms of the IDH1 and IDH2 enzymes.
机译:对于编辑:尽管T细胞淋巴瘤预后差,但这些癌症的遗传基础定义不足。 我们发现了人髓样癌和T细胞淋巴瘤中获得的TET2突变。 TET蛋白参与转录的表观遗传控制,至少通过甲基化胞嘧啶和DNA去甲基化氧化。TET蛋白的催化活性被2-羟基凝集率抑制,由IDH1的突变形式产生的致癌代谢物 和IDH2酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号